Rescue of social behavior impairment by clozapine and alterations in the expression of neuronal receptors in a rat model of neurodevelopmental impairment induced by GRPR blockade

We have previously shown that pharmacological blockade of the gastrin-releasing peptide receptor (GRPR) during the neonatal period in rats produces behavioral features of developmental neuropsychiatric disorders. Here, we show that social interaction deficits in this model are reversed by the atypical antipsychotic clozapine given in the adulthood. In addition, we analyzed the mRNA expression of three neuronal receptors potentially involved in the etiology of disorders of the autism spectrum. Rats were injected with the GRPR antagonist RC-3095 or saline (SAL) from postnatal days 1–10, and tested for social behavior and recognition memory in the adulthood. One hour prior to the behavioral testing, rats were given a systemic injection of clozapine or saline. The mRNA expression of the NR1 subunit of the N-methyl-D-aspartate (NMDA) receptor, the epidermal growth factor receptor (EGFR), and GRPR was measured in the hippocampus and cortex of a separate set of rats given RC-3095 or SAL neonatally. Rats given neonatal RC-3095 showed decreased social interaction and impaired object recognition memory. Clozapine rescued the social interaction impairment. Neonatal treatment with RC-3095 also resulted in dose-dependent decreases in the expression of GRPR, NR1, and EGFR in the cortex, whereas all three receptor mRNAs were increased in the hippocampus in rats treated with the lower dose of RC-3095. The results contribute to further validate the novel rat model of neurodevelopmental disorders induced by GRPR blockade, and shows alterations in the expression of neuronal receptors in this model.

[1]  A. Schally,et al.  A single in vivo administration of bombesin antagonist RC-3095 reduces the levels and mRNA expression of epidermal growth factor receptors in MXT mouse mammary cancers. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[2]  G. Gobbi,et al.  Long-term treatment with clozapine in an adult with autistic disorder accompanied by aggressive behaviour. , 2001, Journal of psychiatry & neuroscience : JPN.

[3]  K. Hashimoto,et al.  Decreased Serum Levels of Epidermal Growth Factor in Adult Subjects with High-Functioning Autism , 2007, Biological Psychiatry.

[4]  M. Bogo,et al.  Expression mapping of ectonucleotide pyrophosphatase/phosphodiesterase 1-3 (E-NPP1–3) in different brain structures during rat development , 2008, International Journal of Developmental Neuroscience.

[5]  K. Groot,et al.  Inhibition of growth of ES-2 human ovarian cancers by bombesin antagonist RC-3095, and luteinizing hormone-releasing hormone antagonist Cetrorelix. , 2001, Cancer letters.

[6]  M. Carlsson,et al.  Hypothesis: Is infantile autism a hypoglutamatergic disorder? Relevance of glutamate – serotonin interactions for pharmacotherapy , 1998, Journal of Neural Transmission.

[7]  Jacqueline N. Crawley,et al.  Development of a mouse test for repetitive, restricted behaviors: Relevance to autism , 2008, Behavioural Brain Research.

[8]  E K Perry,et al.  Autism as a disorder of neural information processing: directions for research and targets for therapy* , 2004, Molecular Psychiatry.

[9]  D. Lowe,et al.  Clozapine promotes approach-oriented behavior in male mice. , 1994, The Journal of clinical psychiatry.

[10]  J. M. Ree,et al.  Involvement of opioid and dopaminergic systems in isolation-induced pinning and social grooming of young rats , 1989, Neuropharmacology.

[11]  H. Anisman,et al.  Effects of gastrin-releasing peptide agonist and antagonist administered to the basolateral nucleus of the amygdala on conditioned fear in the rat , 2008, Psychopharmacology.

[12]  R. Roesler,et al.  Impairments of social behavior and memory after neonatal gastrin-releasing peptide receptor blockade in rats: Implications for an animal model of neurodevelopmental disorders , 2007, Neuropharmacology.

[13]  J. Pevsner,et al.  Postmortem brain abnormalities of the glutamate neurotransmitter system in autism , 2001, Neurology.

[14]  Ryszard Przewłocki,et al.  Behavioral Alterations in Rats Prenatally Exposed to Valproic Acid: Animal Model of Autism , 2005, Neuropsychopharmacology.

[15]  P. Bolton,et al.  Autism and multiple exostoses associated with an X;8 translocation occurring within the GRPR gene and 3' to the SDC2 gene. , 1997, Human molecular genetics.

[16]  R. Jensen,et al.  Analysis of the gastrin‐releasing peptide receptor gene in Italian patients with autism spectrum disorders , 2008, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[17]  O. Guillin,et al.  Effectiveness of clozapine for the treatment of aggression in an adolescent with autistic disorder. , 2010, Journal of child and adolescent psychopharmacology.

[18]  C. McDougle,et al.  Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. , 2008, The Journal of clinical psychiatry.

[19]  R. Jensen,et al.  Mammalian Bombesin Receptors : Nomenclature , Distribution , Pharmacology , Signaling , and Functions in Normal and Disease States , 2008 .

[20]  N. Kato,et al.  Gastrin-releasing peptide receptor (GRPR) locus in Japanese subjects with autism , 2004, Brain and Development.

[21]  T. Nickl-Jockschat,et al.  The role of neurotrophic factors in autism , 2011, Molecular Psychiatry.

[22]  M. Ceylan,et al.  Increased Serum Levels of Epidermal Growth Factor in Children with Autism , 2011, Journal of autism and developmental disorders.

[23]  R. Roesler,et al.  Phosphoinositide 3-kinase is required for bombesin-induced enhancement of fear memory consolidation in the hippocampus , 2009, Peptides.

[24]  R. Roesler,et al.  Neonatal gastrin-releasing peptide receptor blockade reduces maternal odor preference in rats , 2010, Behavioural Brain Research.

[25]  I. Izquierdo,et al.  Molecular mechanisms mediating gastrin-releasing peptide receptor modulation of memory consolidation in the hippocampus , 2006, Neuropharmacology.

[26]  Marc G Caron,et al.  Mice with Reduced NMDA Receptor Expression Display Behaviors Related to Schizophrenia , 1999, Cell.

[27]  R. Roesler,et al.  Gastrin-releasing peptide receptor as a molecular target for psychiatric and neurological disorders. , 2006, CNS & neurological disorders drug targets.

[28]  E. Hattori,et al.  SNP analyses of growth factor genes EGF, TGFbeta-1, and HGF reveal haplotypic association of EGF with autism. , 2007, Biochemical and biophysical research communications.

[29]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[30]  R. Roesler,et al.  Amelioration of recognition memory impairment associated with iron loading or aging by the type 4-specific phosphodiesterase inhibitor rolipram in rats , 2008, Neuropharmacology.

[31]  A. Young,et al.  A systematic review of the use of atypical antipsychotics in autism , 2002, Journal of psychopharmacology.